Sec Form 4 Filing - Venrock Healthcare Capital Partners II, L.P. @ Tricida, Inc. - 2022-06-02

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Venrock Healthcare Capital Partners II, L.P. 2. Issuer Name and Ticker or Trading Symbol Tricida, Inc. [ TCDA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O VENROCK, 3340 HILLVIEW AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 06/02/2022 (Street) PALO ALTO, CA94304 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/02/2022 P 61,722( 1 ) A $ 8.78( 2 ) 5,736,011 I By Funds( 3 ) Common Stock 06/03/2022 P 37,643( 4 ) A $ 9.33( 5 ) 5,773,654 I By Funds( 3 ) Common Stock 06/06/2022 P 91,506( 6 ) A $ 9.35( 7 ) 5,865,160 I By Funds( 3 )

V Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Venrock Healthcare Capital Partners II, L.P. C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X VHCP Co-Investment Holdings II, LLC C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X VHCP Management II, LLC C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X Venrock Healthcare Capital Partners III, L.P. C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X VHCP Co-Investment Holdings III, LLC C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X VHCP Management III, LLC C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X Venrock Healthcare Capital Partners EG, L.P. C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X VHCP Management EG, LLC C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X Koh Bong Y C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X Shah Nimish P C/O VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CA94304 X Signatures /s/ David L. Stepp, Authorized Signatory 06/06/2022 Signature of Reporting Person Date David L. Stepp, Authorized Signatory 06/06/2022 Signature of Reporting Person Date David L. Stepp, Authorized Signatory 06/06/2022 Signature of Reporting Person Date David L. Stepp, Authorized Signatory 06/06/2022 Signature of Reporting Person Date David L. Stepp, Authorized Signatory 06/06/2022 Signature of Reporting Person Date David L. Stepp, Authorized Signatory 06/06/2022 Signature of Reporting Person Date David L. Stepp, Authorized Signatory 06/06/2022 Signature of Reporting Person Date David L. Stepp, Authorized Signatory 06/06/2022 Signature of Reporting Person Date David L. Stepp, Attorney-in-fact 06/06/2022 Signature of Reporting Person Date David L. Stepp, Attorney-in-fact 06/06/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Consists of (i) 6,407 shares purchased by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), (ii) 2,592 shares purchased by VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"), (iii) 13,857 shares purchased by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (iv), 1,383 shares purchased by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (v) 37,483 shares purchased by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). ( 2 )The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.73 to $8.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. ( 3 )VHCP Management II, LLC ("VHCPM II") is the general partner of VHCP II and the manager of VHCP Co-2. VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. ( 4 )Consists of (i) 3,907 shares purchased by VHCP II, (ii) 1,581 shares purchased by VHCP Co-2, (iii) 8,451 shares purchased by VHCP III, (iv) 843 shares purchased by VHCP Co-3 and (v) 22,861 shares purchased by VHCP EG. ( 5 )The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.11 to $9.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. ( 6 )Consists of (i) 9,498 shares purchased by VHCP II, (ii) 3,843 shares purchased by VHCP Co-2, (iii) 20,543 shares purchased by VHCP III, (iv) 2,050 shares purchased by VHCP Co-3 and (v) 55,572 shares purchased by VHCP EG. ( 7 )The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.16 to $9.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. Se e 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.